|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.510 USD | -0.44% |
|
-0.86% | +27.70% |
| 02-03 | Obesity stocks slump on Novo's underwhelming 2026 sales forecast | RE |
| 01-28 | Barclays Initiates Coverage on Altimmune With Overweight Rating, $20 Price Target | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -16.1 | -22.86 | -25.73 | -25 | -36.85 | |||||
Return on Total Capital | -17.52 | -24.76 | -28.31 | -27.38 | -40.31 | |||||
Return On Equity % | -36.14 | -45.69 | -44.07 | -46.63 | -59.86 | |||||
Return on Common Equity | -36.14 | -45.69 | -44.07 | -46.63 | -59.86 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | -309.4 | -1.57K | 104K | -15.35K | -411K | |||||
SG&A Margin | 161.39 | 349.48 | -25.2K | 4.26K | 105K | |||||
EBITDA Margin % | -467.14 | -1.91K | 129K | -19.49K | -515K | |||||
EBITA Margin % | -470.21 | -1.92K | 129K | -19.6K | -516K | |||||
EBIT Margin % | -470.78 | -1.92K | 129K | -19.6K | -516K | |||||
Income From Continuing Operations Margin % | -599.2 | -2.2K | 125K | -20.76K | -475K | |||||
Net Income Margin % | -599.2 | -2.2K | 125K | -20.76K | -475K | |||||
Net Avail. For Common Margin % | -599.2 | -2.2K | 125K | -20.76K | -475K | |||||
Normalized Net Income Margin | -291.66 | -1.2K | 77.96K | -11.15K | -297K | |||||
Levered Free Cash Flow Margin | -314.44 | -1.19K | 62.34K | -11.73K | -224K | |||||
Unlevered Free Cash Flow Margin | -314.37 | -1.19K | 62.33K | -11.73K | -224K | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.05 | 0.02 | -0 | 0 | 0 | |||||
Fixed Assets Turnover | 4.35 | 2.1 | -0.03 | 0.32 | 0.01 | |||||
Receivables Turnover (Average Receivables) | 2.91 | 1.75 | -0.23 | 0.66 | 0.02 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 19.16 | 11.17 | 11.31 | 17.26 | 13.11 | |||||
Quick Ratio | 18.99 | 10.73 | 10.99 | 16.69 | 12.9 | |||||
Operating Cash Flow to Current Liabilities | -2.86 | -4.28 | -3.67 | -6.24 | -7.63 | |||||
Days Sales Outstanding (Average Receivables) | 125.91 | 208.51 | -1.62K | 550.07 | 15.14K | |||||
Average Days Payable Outstanding | 3.44 | 6.54 | 17.71 | 19.07 | 5.08 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 0.81 | 0.77 | 0.61 | 0.35 | 1.36 | |||||
Total Debt / Total Capital | 0.8 | 0.76 | 0.6 | 0.34 | 1.34 | |||||
LT Debt/Equity | 0.65 | 0.56 | 0.36 | 0.09 | 1.14 | |||||
Long-Term Debt / Total Capital | 0.64 | 0.56 | 0.36 | 0.09 | 1.12 | |||||
Total Liabilities / Total Assets | 7.85 | 9.01 | 10.46 | 7.85 | 11.34 | |||||
EBIT / Interest Expense | -4.09K | -15K | -10.96K | -2.39K | -11.46K | |||||
EBITDA / Interest Expense | -4.02K | -14.81K | -10.89K | -2.36K | -11.38K | |||||
(EBITDA - Capex) / Interest Expense | -4.04K | -16.96K | -10.9K | -2.36K | -11.38K | |||||
Total Debt / EBITDA | -0.05 | -0.02 | -0.01 | -0.01 | -0.02 | |||||
Net Debt / EBITDA | 5.66 | 2.25 | 2.11 | 2.39 | 1.27 | |||||
Total Debt / (EBITDA - Capex) | -0.05 | -0.02 | -0.01 | -0.01 | -0.02 | |||||
Net Debt / (EBITDA - Capex) | 5.63 | 1.97 | 2.11 | 2.39 | 1.27 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 41.09 | -46.12 | -101.54 | -726.47 | -95.31 | |||||
Gross Profit, 1 Yr. Growth % | 124.82 | 174.17 | 1.57 | -7.3 | 25.75 | |||||
EBITDA, 1 Yr. Growth % | 97.32 | 121.21 | 3.94 | -4.74 | 23.97 | |||||
EBITA, 1 Yr. Growth % | 96.19 | 120.4 | 3.31 | -4.73 | 23.54 | |||||
EBIT, 1 Yr. Growth % | 94.96 | 120.18 | 3.31 | -4.73 | 23.54 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 139.01 | 97.96 | -12.75 | 4.41 | 7.48 | |||||
Net Income, 1 Yr. Growth % | 139.01 | 97.96 | -12.75 | 4.41 | 7.48 | |||||
Normalized Net Income, 1 Yr. Growth % | 102.33 | 122.59 | -0.23 | -10.37 | 25.03 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 19.72 | 22.94 | -23.04 | -8.23 | -19.4 | |||||
Accounts Receivable, 1 Yr. Growth % | 351.46 | -90.7 | -59.67 | 542.2 | -51.04 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 8.78 | 14.55 | -25.33 | -39.53 | 102.37 | |||||
Total Assets, 1 Yr. Growth % | 353.43 | -10.71 | -5.45 | 1.79 | -33.87 | |||||
Tangible Book Value, 1 Yr. Growth % | 549.79 | -12.36 | -7.41 | 12.28 | -36.37 | |||||
Common Equity, 1 Yr. Growth % | 396.21 | -11.84 | -6.95 | 4.75 | -36.37 | |||||
Cash From Operations, 1 Yr. Growth % | 258.64 | 128.06 | -20.01 | 21.13 | 5.33 | |||||
Capital Expenditures, 1 Yr. Growth % | 16.52K | 5.84K | -98.96 | -62.7 | - | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 220.69 | 105.28 | -19.35 | 19.88 | -10.23 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 220.67 | 105.31 | -19.36 | 19.84 | -10.2 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -10.99 | -12.81 | -90.89 | -68.92 | -45.77 | |||||
Gross Profit, 2 Yr. CAGR % | 76.51 | 148.27 | 66.87 | -2.97 | 7.97 | |||||
EBITDA, 2 Yr. CAGR % | 47.43 | 108.57 | 51.63 | -0.75 | 8.67 | |||||
EBITA, 2 Yr. CAGR % | 47 | 107.94 | 50.91 | -0.79 | 8.49 | |||||
EBIT, 2 Yr. CAGR % | 46.75 | 107.19 | 50.82 | -0.79 | 8.49 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 11.9 | 117.52 | 31.43 | -4.55 | 5.93 | |||||
Net Income, 2 Yr. CAGR % | 11.9 | 117.52 | 31.43 | -4.55 | 5.93 | |||||
Normalized Net Income, 2 Yr. CAGR % | 36.9 | 112.22 | 49.02 | -5.44 | 5.86 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -64.47 | 21.32 | -2.73 | -15.96 | -14 | |||||
Accounts Receivable, 2 Yr. CAGR % | 15.4 | -35.2 | -80.63 | 60.93 | 77.33 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 20.84 | 11.62 | -7.52 | -32.81 | 10.62 | |||||
Total Assets, 2 Yr. CAGR % | 111.59 | 101.21 | -8.12 | -1.9 | -17.95 | |||||
Tangible Book Value, 2 Yr. CAGR % | 148.65 | 138.63 | -9.92 | 1.96 | -15.48 | |||||
Common Equity, 2 Yr. CAGR % | 116.22 | 109.16 | -9.43 | -1.27 | -18.36 | |||||
Cash From Operations, 2 Yr. CAGR % | 91.52 | 185.45 | 35.07 | -1.56 | 12.95 | |||||
Capital Expenditures, 2 Yr. CAGR % | -54.27 | 9.84K | -21.4 | -93.77 | - | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 325.75 | 155.92 | 28.66 | -2.49 | 3.74 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 326.46 | 155.94 | 28.67 | -2.51 | 3.74 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | -8.65 | -24.7 | -77.28 | -62.66 | -83.45 | |||||
Gross Profit, 3 Yr. CAGR % | 48.92 | 104.42 | 84.31 | 37.18 | 5.79 | |||||
EBITDA, 3 Yr. CAGR % | 33.73 | 68.59 | 65.36 | 29.65 | 6.89 | |||||
EBITA, 3 Yr. CAGR % | 33.79 | 68.25 | 64.71 | 29.46 | 6.74 | |||||
EBIT, 3 Yr. CAGR % | 33.69 | 68 | 64.3 | 29.41 | 6.74 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 1.85 | 35.33 | 60.42 | 21.72 | -0.7 | |||||
Net Income, 3 Yr. CAGR % | 1.85 | 35.33 | 60.42 | 21.72 | -0.7 | |||||
Normalized Net Income, 3 Yr. CAGR % | 33.25 | 60.98 | 65.01 | 25.79 | 3.79 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -74.76 | -46.27 | 4.24 | -4.6 | -17.12 | |||||
Accounts Receivable, 3 Yr. CAGR % | 6.6 | -50.15 | -44.67 | -37.77 | 8.24 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 48.14 | 18.7 | -2.38 | -19.73 | -2.97 | |||||
Total Assets, 3 Yr. CAGR % | 57.26 | 58.71 | 56.43 | -4.93 | -13.98 | |||||
Tangible Book Value, 3 Yr. CAGR % | 581.35 | 75.64 | 74.05 | -3.06 | -12.87 | |||||
Common Equity, 3 Yr. CAGR % | 78.98 | 60.34 | 59.67 | -4.93 | -14.72 | |||||
Cash From Operations, 3 Yr. CAGR % | 19.43 | 102.74 | 86.8 | 30.25 | 0.68 | |||||
Capital Expenditures, 3 Yr. CAGR % | 21.96 | 131.6 | 368.28 | -38.69 | - | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 3.86 | 233.28 | 74.15 | 24.97 | -5.14 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 3.86 | 233.67 | 74.16 | 24.96 | -5.14 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 11.95 | 6.39 | -63.67 | -47.15 | -67.83 | |||||
Gross Profit, 5 Yr. CAGR % | 128.2 | 77.1 | 55.86 | 51.73 | 48.81 | |||||
EBITDA, 5 Yr. CAGR % | 49.05 | 52.31 | 40.53 | 36.39 | 39.65 | |||||
EBITA, 5 Yr. CAGR % | 48.95 | 52.31 | 40.39 | 36.21 | 39.37 | |||||
EBIT, 5 Yr. CAGR % | 48.76 | 52.11 | 40.3 | 36.08 | 39.17 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 49.13 | 54.34 | 12.78 | 17.69 | 35.88 | |||||
Net Income, 5 Yr. CAGR % | 49.13 | 54.34 | 12.78 | 17.69 | 35.88 | |||||
Normalized Net Income, 5 Yr. CAGR % | 48.16 | 52.18 | 39.35 | 30.12 | 38.17 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -40.88 | -45.68 | -56.7 | -35.74 | -3.48 | |||||
Accounts Receivable, 5 Yr. CAGR % | 55.1 | 2.28 | -46.11 | -20.33 | -11.83 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 73.1 | 66.06 | 22.69 | -5.46 | 2.63 | |||||
Total Assets, 5 Yr. CAGR % | 38.22 | 41.63 | 26.84 | 30.93 | 20.84 | |||||
Tangible Book Value, 5 Yr. CAGR % | 137.54 | 162.02 | 203.3 | 41.3 | 30.38 | |||||
Common Equity, 5 Yr. CAGR % | 39.26 | 43.96 | 36.3 | 32.07 | 22.1 | |||||
Cash From Operations, 5 Yr. CAGR % | 46.58 | 65.23 | 25.36 | 51.85 | 52.75 | |||||
Capital Expenditures, 5 Yr. CAGR % | 18.77 | 149.65 | 2.3 | -45.48 | - | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 76.94 | 92.78 | 13.03 | 103.85 | 41.09 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 77.77 | 93.26 | 13.03 | 103.98 | 41.09 |
- Stock Market
- Equities
- ALT Stock
- Financials Altimmune, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















